Polish Pharmacoeconomic Society activities review 1/2017
In the first half of 2017 Polish Pharmacoeconomic Society intensified cooperation with its sections. In March, a meeting of members of the Management Board with representatives of the different sections took place. A decision was made to involve Polish Pharmacoeconomic Society in legal consultations and to initiate a dialogue with HTA Agency (AOTMiT) in order to develop good HTA practices in Poland and to consult possible doubts that may arise around the process of preparing the HTA reports.
As a result of the meeting with the students’ representatives, the Pharmacoeconomic Society became the caring institution of ISPOR Poland Student Chapter and Professor Marcin Czech became the tutor.
Since the second quarter of 2017, the Management Board members have started working on the content and logistics of the 15th International Pharmacoeconomic Conference, whose main subject will be "Drug pricing in Europe - fair, uniform or both?". The Conference is planned for December 2017 in Warsaw.
Since August 2017, the Pharmacoeconomic Society President-Elect Professor Marcin Czech assumed the duties of Undersecretary of State at the Ministry of Health.
On 23- 24th March 2017 the Journal of Health Policy and Outcomes Research organized the IV Scientific Conference dedicated to Asthma and Immunological diseases.
The Ministry of Health representative shared information from the project dedicated to mapping the health needs.
The topics related to asthma, among others, included Drug Program update, current treatment for severe asthma, psychological aspects of asthma treatment and treatment cost analysis.
The Immunology session was dedicated for the discussion on the following topic: the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Polish drug programs in comparison with the recommendations of EULAR; Non-specific inflammatory bowel diseases - goals and treatment options; autoinflammatory disorders; psoriasis, multiple sclerosis, ulcerative colitis treatment costs as well as an analysis of autoimmune diseases data from the National Health Fund.